Rezolute Inc (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company developing treatments for rare metabolic diseases driven by insulin dysregulation. The company generates no product revenue, funding operations entirely through equity and debt financings, including private placements and underwritten public offerings. Its lead program is ersodetug (formerly XOMA 358 or RZ358), a monoclonal antibody licensed exclusively from XOMA in December 2017 for the treatment of congenital hyperinsulinism (HI). As of the FY2025 10-K filing date, five patients with congenital HI were receiving ersodetug through an Expanded Access Program, and the company was advancing the Phase 3 sunRIZE clinical trial. Total operating expenses were $79.9 million for FY2025 (fiscal year ended June 30, 2025), comprising $61.5 million in research and development and $18.4 million in general and administrative costs, producing an operating loss of $79.9 million. Rezolute appointed a Chief Commercial Officer in August 2025, signaling preparation for a potential commercial launch. The company requires additional financing to fund long-term obligations beyond 12 months from the FY2025 financial statement issuance date.

Revenue model

No product revenue as of FY2025 (fiscal year ended June 30, 2025). Operations are funded through equity issuances, including underwritten public offerings, private placements, and pre-funded warrants. The company holds an exclusive global license from XOMA to develop and commercialize ersodetug, with ongoing licensing payment obligations to both XOMA and ActiveSite.

Products and services

Ersodetug (formerly XOMA 358, RZ358): an insulin receptor antibody licensed from XOMA, in Phase 3 clinical development for congenital hyperinsulinism (HI). Five patients were receiving ersodetug through an Expanded Access Program as of the FY2025 10-K filing. The Phase 3 program is the sunRIZE clinical trial.

Customers and end markets

Target patient population is individuals with congenital hyperinsulinism, a rare pediatric and adult metabolic disorder. The Expanded Access Program has served patients refractory to standard therapies, including one infant for whom off-label or surgical options such as pancreatectomy were being considered. No commercial customers as of FY2025.

Value-chain role

Clinical-stage drug developer. Rezolute licenses intellectual property from third parties (XOMA, ActiveSite), conducts and sponsors clinical trials, and relies on external manufacturing for clinical supply. No commercial manufacturing or distribution operations as of FY2025.

Geographic exposure

Holds an exclusive global license for ersodetug covering all indications. Specific geographic breakdown of clinical trial sites or operational spend is not disclosed in the filing excerpts.

Source: SEC 10-K, filed 2025-09-17

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Candel Therapeutics Inc Lunai Bioworks Inc Greenwich Lifesciences Inc Biostax Corp. MediciNova Inc Shattuck Labs Inc XBiotech Inc